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Background/aim: Autism is a neurodevelopmental disorder identified with higher frequency of serotonin abnormalities and
gastrointestinal (GI) and sleep problems. This study aimed to evaluate the plasma levels of serotonin, GI symptoms, and sleep problems,
and their relationship with autism severity in children with autism.
Materials and methods: Thirty-five children with autism and 31 healthy subjects were studied. GI problems, sleep disorders, and
severity of disorder were assessed. Plasma serotonin was determined using ELISA.
Results: There was no significant association between GI problems and autism severity, but a significant positive correlation was seen
between different indicators of sleep disorder and severity of autism. Plasma levels of serotonin were significantly higher in autistic
children and a significant negative correlation was observed between plasma levels of serotonin and autism severity (r = –0.39, P = 0.02).
Conclusion: Elevated plasma serotonin in autistic children and its negative correlation with disease severity may indicate involvement
of the neurotransmitter in the neurophysiologic mechanism of autism.
Key words: Autism, serotonin, gastrointestinal symptoms, sleep problems, autism severity

1. Introduction
Autism is a neurodevelopmental and behaviorally defined
disorder with multiple genetic and environmental risk
factors that develops typically in the few first years of life
(1). Several reports have suggested that gastrointestinal
(GI) disorders and sleep disturbances are present in higher
frequency among autistic children than in those typically
developing (2–6). It has been described that 22.7%–84%
of autistic children experience GI symptoms such as
constipation, abdominal pain, diarrhea, and gastric
irritation (7–9). In addition, it has been reported that
25%–80% of children with autism have sleep problems,
including sleeping less, waking up more during the night,
early morning awakening, shortened night’s sleep, and
parasomnia (10). Disturbed sleep potentially aggravates
autism-related indicators, including over-activity,
disruptive behavior, social difficulties, and disease severity
(4,11).
Serotonin or 5-hydroxy tryptamine (5-HT) is a
neurotransmitter derived from tryptophan and mainly
found in the GI tract, blood platelets, and the central
nervous system (CNS). It regulates a variety of behavioral,
* Correspondence: parinaz.kalejahi@gmail.com

autonomic, and cognitive functions. Altered blood
serotonin levels were the first biomarker found in autism
studies (12,13). Rodent studies indicate a serotonin
abnormality can occur during the development of autism.
An animal study has reported that mice genetically depleted
of brain serotonin demonstrate behavioral phenotypes
that are greatly characteristic of autism, including social
impairments, communication deficits, and repetitive
behaviors (14). There is also evidence that reduction
of placenta-derived serotonin levels during embryonic
pregnancy leads to hypo-serotonergic situations in the
forebrain of the fetus and causes autism (15). Clinical
observations include both elevated and lowered levels of
the neurotransmitter in subjects with autism compared to
controls (16,17). Some investigations have reported that
about one-third of autistic patients have elevated levels of
whole blood or platelet serotonin (18,19).
According to previous studies, serotonin is indirectly
involved in regulating the sleep–wake cycle through
its metabolite melatonin (20,21). Moreover, it has been
reported that supplementation with 5-hydroxy tryptophan
(metabolic intermediate in the biosynthesis of serotonin
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and melatonin) regulated sleep and circadian sleep–wake
rhythm in animals (22,23). Furthermore, changes in
serotonin signaling have been demonstrated in the number
of gastrointestinal diseases, including inflammatory
bowel disease, irritable bowel syndrome, postinfectious
irritable bowel syndrome, and idiopathic constipation
(24,25). Taking these results together, it is postulated that
serotonergic abnormalities are possibly associated with the
clinical features of autism.
It appears that understanding any possible relation
between plasma levels of serotonin with autism severity
and both GI symptoms and sleep problems will be of
help for better clarifying the pathogenesis and further
management of these important two co-morbidities in
autism. Therefore, this study aimed to evaluate plasma
levels of serotonin, GI symptoms, and sleep problems,
and their relationship with autism severity in children and
adolescents diagnosed with autism.
2. Materials and methods
2.1. Participants
In this case-control cross-sectional study, 35 children
and adolescents with autism (24 boys, 11 girls) and 31
typically developing healthy children (18 boys, 13 girls) as
a control group, aged 4–18 years, participated. The patients
met the diagnostic criteria of autism according to the 4th
edition of the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR) through diagnostic interview
by a psychiatrist. The control group was healthy and
normally developing children who attended the outpatient
department of pediatric hospital for routine health care
and matched for age and sex with the autistic group.
Inclusion criteria for the autism group were no current use
of any chelation treatment or prior diagnosis of autism,
according to psychiatrist interviews and DSM-IV-TR
criteria. Good mental and physical health according to
the Strengths and Difficulties Questionnaire (SDQ) was
the inclusion criterion for the control group. Subjects with
neurological diseases such as cerebral palsy and tuberous
sclerosis and metabolic disorders such as phenylketonuria
were excluded.
The parents were asked to answer a self-constructed
questionnaire about demographic information such as
age, medicine consumption, age of parent and level of
education, and presence or absence of epilepsy and other
diseases. The study was approved by the Ethical Committee
at Tabriz University of Medical Sciences, Tabriz, Iran.
Informed consent was obtained from the subjects or their
parents.
2.2. Blood collection
Venous blood samples were collected from both groups in
test tubes containing sodium heparin as an anticoagulant.
Samples were centrifuged at 3500 rpm at room temperature
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for 15 min. Poor platelet plasma was obtained and deep
frozen at –70 °C until analysis time.
2.3. Assessment of autism severity
The Gilliam Autism Rating Scale (GARS) was used to
confirm the diagnosis of autism and assess the severity
of the disorder. The severity of autism was categorized
as mild (score ≤52), moderate (score = 53–84), or severe
(score ≥85), according to the GARS scale.
2.4. Assessment of gastrointestinal problems
The Rome III version (QPGS-III) questionnaire was used
to evaluate gastrointestinal symptoms. The tool includes
multiple sets of questions for evaluating functional
dyspepsia, upper and lower abdominal pain associated
with bowel symptoms, abdominal migraine, functional
abdominal pain, constipation, nonretentive fecal
incontinence, aerophagia, cyclic vomiting syndrome, and
adolescent rumination syndrome.
2.5. Assessment of sleep problems
The Children’s Sleep Habits Questionnaire-Abbreviated
(CSHQ-A) was used as a screening tool to identify sleep
disturbances such as bedtime resistance, sleep onset delay,
and parasomnias. CSHQ-A is a 33-item questionnaire in
which each item is rated on a three-point scale: 1 = rarely
(0–1 time/week); 2 = sometimes (2–4 times/week); 3 =
usually (5–7 times/week). Each question was asked in
relation to the previous week.
2.6. Measurement of plasma serotonin
Plasma serotonin concentration was determined using a
serotonin ELISA kit (LDN GmbH & Co. KG, Nordhorn,
Germany). First, 25 µL of the acylated standards, controls,
and samples were pipetted into the appropriate wells of the
serotonin microtiter strips. Then 100 µL of the serotonin
antiserum was added to all wells and they were incubated
for 30 min at room temperature. All wells were washed 3
times thoroughly using wash buffer and incubated for 15
min after 100 µL of the conjugate was added. Finally, 100
µL of the substrate was pipetted into all wells and after 15
min incubation on a shaker 100 µL of the stop solution
was added. The absorbance of the solution in the wells was
read within 10 min using a microplate reader set to 450
nm.
2.7. Statistical analysis
The data were analyzed using SPSS, version 16.0.
Demographic characteristics of the participants were
summarized by either mean ± standard deviation (SD) for
continuous data or percentage (frequency) for proportional
data. Differences between the two groups were assessed
by independent sample t-test for normally distributed
data, Mann–Whitney U test for nonparametric variables,
and chi-square test for qualitative data. Spearman’s
coefficient correlations were determined for associations
between variables. P-values less than 0.05 were considered
statistically significant.
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3. Results
3.1. Participant Characteristics
Thirty-five children with autism and 31 healthy subjects,
as a control group, completed the study. The mean ± SD of
age for children with autism was 8.1 ± 4.0 years and for the
control group was 7.3 ± 2.6. Demographics characteristics
of all subjects are shown in Table 1. In the autism group,
the percentage of mothers and fathers with high education
was nonsignificantly greater than that in the control group.
There were also no significant differences between the two
groups in terms of demographic factors.
3.2. Gastrointestinal symptoms
In the autism group, 57.1% (n = 20) of the children had
gastrointestinal problems, but only 3.2% (n = 1) of the
control children were suffering from GI problems based
on parent reports. The observed difference between the
two groups was statistically significant (P < 0.01).
Then for a more accurate assessment of the problems
we used a questionnaire on pediatric gastrointestinal

symptoms, Rome III version (QPGS- III). Based on this
questionnaire, 44.1% of autistic children had GI problems
as shown in Table 2. The most common gastrointestinal
symptom was constipation (n = 10, 15.2%).
3.3. Sleep problems
A comparison of CSHQ scale scores for the autism
and control groups is shown in Table 3. There were
significant differences in bedtime resistance, sleep anxiety,
parasomnias, daytime sleepiness, and total scale score (P
< 0.05) between the two groups. There were no significant
differences with sleep duration, sleep onset delay, or night
waking subscales (P > 0.05).
3.4. Plasma level of serotonin and its association with GI
and sleep dysfunction and demographic factors
As shown in the Figure, the autism group had significantly
higher plasma serotonin levels (2.73 ± 0.61 ng/mL) than
the healthy children (2.35 ± 0.31 ng/mL) (P = 0.002). No
significant correlation was found between plasma levels of
serotonin and all medications used.

Table 1. Sociodemographic characteristics of autistic and control groups.
Characteristics

Autism (n = 35)

Control (n = 31)

P

Sex *
-

68.6 (24)
31.4 (11)

58.1 (18)
41.9 (13)

0.38

Age (year)**

8.1 ± 4.0

7.3 ± 2.6

0.34

Area of residence*
Urban
Rural

82.9 (29)
17.1 (6)

77.4 (24)
22.6 (7)

0.57

Education of mother*
<High school
High school only
College/postgraduate degree

51.4 (18)
28.6 (10)
20.0 (7)

67.7 (21)
32.3 (10)
0 (0)

0.07

Education of father*
<High school
High school only
College/postgraduate degree

42.9 (15)
34.3 (12)
22.9 (8)

61.3 (19)
29.0 (9)
9.7 (3)

0.09

Occupation of mother*
Working
Housewife/retired

14.3 (5)
85.7 (30)

3.2 (1)
96.8 (30)

0.25

Ordinal position of child*
First born
Second born or later

54.3 (19)
45.7 (16)

58.1 (18)
41.9 (13)

0.78

Medications*
Yes

97.1 (34)

0 (0)

<0.001

2.9 (1)

100 (31)

-

Male
Female

No

* expressed as percent (number); ** expressed as mean ± SD.
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Table 2. Symptoms of gastrointestinal problems.
Symptoms

% (n) with problems

Functional constipation
Cyclic vomiting syndrome
Nonretentive fecal incontinence
Irritable bowel syndrome
Functional abdominal pain
Abdominal migraine
Aerophagia
Adolescent rumination syndrome

15.2 (10)
6.1 (4)
6.1 (4)
3.0 (2)
6.1 (4)
7.6 (5)
0.0 (0)
0.0 (0)

Table 3. Comparison of CSHQa scale scores between autism and control groups.
Case (n = 35)

Control (n = 31)

P

Bedtime resistance

9.23 ± 4.63

6.35 ± 2.19

0.0001*

Sleep onset delay

2.23 ± 0.97

2.57 ± 1.07

0.18

Sleep duration

5.46 ± 1.03

5.52 ± 1.06

0.82

Sleep anxiety

6.06 ± 3.40

4.06 ± 3.18

0.01*

Night wakening

4.00 ± 2.63

3.81 ± 2.40

0.75

Parasomnias

8.89 ± 6.38

3.16 ± 2.05

0.0001*

Sleep-disordered breathing

3.11 ± 2.04

3.87 ± 2.32

0.16

Daytime sleepiness

13.29 ± 4.96

9.97 ± 2.47

0.0001*

Total scores

54.54 ± 18.85

39.29 ± 5.86

0.0001*

Subscale item

Children’s Sleep Habits Questionnaire-Abbreviated
Data are presented as mean ± SD
*P values less than 0.05 were considered statistically significant.
a

Among the problems related to sleep, only sleepdisordered breathing problem was negatively correlated
with plasma levels of serotonin (r = –0.22, P = 0.05). There
was no significant relationship between all indicators
of GI and other sleep disturbances with plasma levels of
serotonin (data not shown).

Figure. Plasma levels of serotonin in autistic (n = 35) and healthy
children (n = 31). The data were generated by the translog and
expressed as mean ± SD.
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3.5. Severity of autism and its association with clinical
and laboratory factors
As shown in Table 4, 17.1% (n = 6) of the autistic children
were recognized with mild, 48.6% (n = 17) with moderate,
and 34.3% (n = 12) with severe disorder level. There was
a significant negative correlation between plasma levels
of serotonin and autism severity (r = –0.39, P = 0.02).
In autistic children, there was no significant correlation
between child’s age and birth rank with the severity of
disease (r = –0.19, P = 0.17), (r = 0.48, P = 0.75).
As shown in Table 5, there were significant correlations
between autism severity and bedtime resistance (r = 0.56,
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Table 4: Severity of autism by sex.
Severity

Boys

Girls

Total

Mild

12.1 (4)

5 (2)

17.1 (6)

Moderate

37.14 (13)

11.46 (4)

48.6 (17)

High

20.1 (7)

14.2 (5)

34.3 (12)

Expressed as a percent (number)
Table 5. Correlation between autism severity and CSHQa scores.
Subscale item

R

P

Bedtime resistance

0.56

0.0001*

Sleep onset delay

–0.10

0.56

Sleep duration

0.75

0.61

Sleep anxiety

0.55

0.0001*

Night wakening

0.30

0. 07

Parasomnias

0.83

0.0001*

Sleep-disordered breathing

0.50

0.0001*

Daytime sleepiness

0.64

0.0001*

Total scores

0.81

0.0001*

a
Children’s Sleep Habits Questionnaire-Abbreviated
*P values less than 0.05 were considered statistically significant.

P < 0.01), sleep anxiety (r = 0.55, P < 0.01), parasomnias
(r = 0.83, P < 0.01), sleep-disordered breathing (r = 0.50,
P < 0.01), daytime sleepiness (r = 0.64, P< 0.01), and
total scores (r = 0.81, P < 0.01). There was no significant
association between any indicators of GI symptoms and
severity of autism.
4. Discussion
In the present study, more than half of the children with
autism were found to have GI problems. Numerous
investigations have indicated the presence of GI problems
in autistic children (2–8). These problems can lead to other
difficulties such as feeding problems, social difficulties,
and autism severity scores (9,26). Finding of the source
of these problems and providing therapy can be helpful
in reducing the severity of disease. The exact cause of the
high rate of GI problems in autistic children is unknown,
but a series of assumptions about the mechanism of these
problems has been proposed: these symptoms may be due
to disruption of endogenous gut microflora promoting
overgrowth of pathogenic microorganisms suspected
to produce neurotoxins (27). GI symptoms may also be

related to a disruption in the mucosal lining of the gut,
causing malabsorption of large proteins such as gliadin
and casein. Peptides derived from gluten and casein fail
to become amino acids and increased gut permeability
then allows the peptides to leak into the blood stream,
where they circulate and eventually cross the brain–blood
barrier, which could ultimately lead to inflammation
and alter neurologic functions (28). A number of studies
have investigated potential changes in mucosal serotonin
signaling in pathologic conditions of the gut, because
the predominant site of serotonin synthesis, storage,
and release is the enterochromaffin cells of the intestinal
mucosa. Changes in serotonin signaling have been
demonstrated in a number of gastrointestinal diseases
(24,25). Another hypothesis is related to the stereotyped
behaviors. Stereotyped diets may result in an inadequate
intake of fiber and fluids or high intakes of processed food,
which can cause gastrointestinal problems (29). Medication
administered to children with autism can influence gut
function; for example, stimulants can cause abdominal
pain (30,31). Finally, in some reports, decreased activity
of digestive enzymes has contributed to GI problems in
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children with autism. Horvath’s study showed that 49%
of children with autism who underwent endoscopy had
deficiencies in one or more disaccharidase enzymes,
especially lactase and maltase (32). This deficiency can
lead to malabsorption and GI problems.
In the current study, children with autism had
significantly more sleeping problems than the control
children. The results show that the autism group had
significantly higher scores in bedtime resistance, sleep
anxiety, parasomnias, sleep-disordered breathing, daytime
sleepiness, and CSHQ total score than the control group.
Our results are in agreement with previous studies
that reported a high prevalence of sleep disturbances
in children with autism (5,6,8). The origin of sleep
disorders such as GI problems is not known. It has been
hypothesized that the sleep difficulties seen in autism are
the result of the aberrant activation of neural circuitry
involved in the control of both rapid eye movement (REM)
and non-REM sleep. Another hypothesis may be related
to production of melatonin. Serotonin is the precursor
for melatonin and impaired plasma or brain levels of
serotonin alter melatonin secretion in humans. It has been
suggested that melatonin regulation may be abnormal in
autism (33). In the present work, a significant correlation
was observed between autism severity and bedtime
resistance, sleep anxiety, parasomnias, sleep-disordered
breathing, daytime sleepiness, and total scores. This result
was similar to Tudor’s study finding indicating a positive
correlation between the severity of sleep problems and the
severity of autism symptoms (34). In another study, it was
demonstrated that fewer hours of sleep per night predict
overall autism severity scores and social skills deficits (5).
In the present work, greater levels of plasma serotonin
were observed in autistic children. Findings from previous
investigations on this topic are inconsistent. Increased
plasma or whole blood levels of serotonin have been
shown in earlier studies. Hranilovic et al. showed that the
platelet serotonin level was significantly higher in autistic
adults than the control sample and hyperserotonemic
subjects made up 32% of the patients (35). Conversely,
Nagwa et al. reported a low level of plasma serotonin in
autistic children compared to controls (36). Inconsistent
findings in the studies evaluating peripheral 5-HT in
autistic patients might be due to differences in sampling
demographics (e.g., age range, sex, ethnicity), patient
characteristics (e.g., hyperactivity grade), subjects
used as controls, 5-HT measurement protocol, place
of 5-HT measurement (serum, plasma or platelet), or
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biomaterials and analytical procedures used (17). The
exact mechanism of the enhanced circulation serotonin
in autistic patients has remained unclear. Different
hypotheses have been expressed in relation to disturbance
of serotonin metabolism in autism. Nakamura et al. in
their study suggested that the hyperserotonemia is related
to serotonin receptor (SERT) dysfunction that leads to
lower serotonin entry into the cell and thus increases the
accumulation of serotonin in the blood (37). Increased
synthesis of 5-HT in the intestine, altered release from
the enterochromaffin cells, and gene dysfunction (e.g., a
mutation in the tryptophan 2,3-dioxygenase gene) have
also been suggested as possible causes (38–41). In the
present study, the neurotransmitter level was negatively
correlated with disease severity and sleep-disordered
breathing problems. An association of hyperserotonemia
with the stereotyped behavior or severity of autism has been
suggested in some studies (42,43). Moreover, research with
animal models has suggested that brain serotonin level
controls sleep–wake behavior. Monti in a study on animals
demonstrated that 5-HT knock-out mice exhibit greater
amounts of REM sleep than their wild-type counterparts
(44). Serotonin receptor knock-out mice also showed a
significant increase in wakefulness and a reduction in
slow wave sleep (44). In agreement with Nakamura et al.’s
suggestion, it is speculated that due to serotonin receptor
signaling disturbance, serotonin is unable to enter the cells
and perform its function and this subsequently leads to
compensatory elevation of serotonin production. High
serotonin levels may function as endogenous feedback
to try to overcome the pathogenesis of autism. However,
more studies are needed to clarify the issue.
The present study found that the incidence of GI
and sleep disorders in autistic children was higher than
in healthy children; on the other hand, a significant
relationship was found between sleep problems and
plasma serotonin level with the severity of the disorder.
Screening of autistic children who suffer from this
problem and application of appropriate treatment can
reduce the severity of symptoms and also ameliorate
feeding problems. Since autism is increasing and adverse
effects are more extensive, studies with larger sample size
are needed.
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